Zusammenfassung
Antipsychotika sind eine chemisch heterogene Gruppe von Pharmaka mit antipsychotischem Wirksamkeitsschwerpunkt und unterschiedlichem NW-Profil. Der häufig synonym verwendete Begriff »Neuroleptikum« wird international immer mehr durch den Begriff Antipsychotikum ersetzt. Dieser weist auf die klinisch bedeutsame therapeutische Wirkung bei psychotischen Störungen, insbesondere schizophrenen Psychosen, hin.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Addington DE, Mohamed S, Rosenheck RA et al (2011) Impact of second-generation antipsychot- ics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry 72(1): 75–80
Citrome L (2011) A systematic review of meta-analyses of the efficacy of oral atypical antipsychot- ics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother 13(11): 1545–1573
Correll CU, Rummel-Kluge C, Corves C et al (2009) Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35(2): 443–457
DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde) (Hrsg) (2006) Behandlungsleitlinie Schizophrenie. Reihe: S3 Praxisleitlinien in Psychiatrie und Psychotherapie, Bd 1. Springer, Berlin Heidelberg New York
DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (2012) S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression; Langfassung Version 1.3. Januar, basierend auf der Fassung von November 2009. AWMF-Register-Nr. nvl-005
Dickerson FB, Lehman AF (2011) Evidence-based psychotherapy for schizophrenia: 2011 update.J Nerv Ment Dis 199(8): 520–526
Gaebel W, Riesbeck M, Wölwer W et al; German Study Group on First-Episode Schizophrenia (2011) Relapse prevention in first-episode schizophrenia - maintenance vs intermittent drug treat- ment with prodrome-based early intervention: results of a randomized controlled trial with- in the German Research Network on Schizophrenia. J Clin Psychiatry 72(2): 205–218
Ho BC, Andreasen NC, Ziebell S et al (2011) Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 68(2): 128–137
Hui WK, Mitchell LB, Kavanagh KM et al (1990) Melperone: electrophysiologic and antiarrhythmic activity in humans. J Cardiovasc Pharmacol 15: 144–149
Kales HC, Kim HM, Zivin K et al (2012) Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 169(1): 71–79
Kelly TM, Daley DC, Douaihy AB (2012) Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav 37(1): 11–24
Kinon BJ, Chen L, Ascher-Svanum H et al (2010) Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychop- harmacology 35: 581–590
Kishimoto T, Agarwal V, Kishi T et al (2011) Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsy- chotics. Mol Psychiatry, Epub ahead of print
Klosterkötter J, Schultze-Lutter F, Bechdolf A, Ruhrmann S (2011) Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry 10(3): 165–174
Leucht S, Corves C, Arbter D et al (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31–41
Leucht C, Heres S, Kane JM et al (2011) Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 127(1-3): 83–92
Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antip- sychotic-related weight gain and metabolic abnormalities: a systematic review and meta- analysis. Neuropsychopharmacology 35(7): 1520–1530
Naber D, Lambert M (2009) The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 23(8): 649–659
Porcelli S, Balzarro B, Serretti A (2012) Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 22(3): 165–182
Ray WA, Chung CP, Murray KT et al (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360(3): 225–235
Röder V, Mueller DR, Schmidt SJ (2011) Effectiveness of integrated psychological therapy (IPT) for schizophrenia patients: a research update. Schizophr Bull 37(Suppl 2): S71–79
Rummel-Kluge C, Komossa K, Schwarz S et al (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123(2-3): 225–233
Rummel-Kluge C, Komossa K, Schwarz S et al (2012) Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 38(1): 167–177
Steinert T, Baier H, Fröscher W, Jandl M (2011) Epileptische Anfälle unter der Behandlung mit Antidepressiva und Neuroleptika. Fortschr Neurol Psychiatr 79(3): 138–143
Tiihonen J, Haukka J, Taylor M et al (2011) A nationwide cohort study of oral and depot anti- psychotics after first hospitalization for schizophrenia. Am J Psychiatry 168(6): 603–609
Tiihonen J, Suokas JT, Suvisaari JM et al (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69: 476–483
Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsades de Pointes. Dtsch Arztebl Int 108(41): 687–693
Wolter DK (2009) Risiken von Antipsychotika im Alter, speziell bei Demenzen. Z Gerontopsychol -psychiatrie 22(1): 17–56
Zhang R, Dong L, Shao F et al (2011) Antipsychotics and venous thromboembolism risk: a meta- analysis. Pharmacopsychiatry 44(5): 183–188
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Benkert, O., Hippius, H. (2013). Antipsychotika. In: Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29810-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-29810-3_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-29809-7
Online ISBN: 978-3-642-29810-3
eBook Packages: Medicine (German Language)